Crossmark

Adaptive designs in clinical trials: why use them, and how to run and report them

Crossref DOI link: https://doi.org/10.1186/s12916-018-1017-7

Published Online: 2018-02-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pallmann, Philip http://orcid.org/0000-0001-8274-9696
Bedding, Alun W.

Choodari-Oskooei, Babak

Dimairo, Munyaradzi

Flight, Laura

Hampson, Lisa V.

Holmes, Jane

Mander, Adrian P.

Odondi, Lang’o

Sydes, Matthew R.

Villar, Sofía S.

Wason, James M. S.

Weir, Christopher J.

Wheeler, Graham M.

Yap, Christina

Jaki, Thomas
Funding

Funding for this research was provided by:

Medical Research Council (MR/L004933/1-R/N/P/B1)

Medical Research Council (MR/K025635/1)

Medical Research Council (MC_UU_12023/29)

Programme Grants for Applied Research (NIHR-SRF-2015-08-001)

Programme Grants for Applied Research (DRF-2015-08-013)

Medical Research Council (MC_UU_12023/24)

Medical Research Council (MC_UU_12023/25)

Medical Research Council (MC_EX_UU_G0800814)

Medical Research Council (G0800860)

Cancer Research UK (C22436/A15958)
More Information

Article History

Received: 10 July 2017

Accepted: 30 January 2018

First Online: 28 February 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: AWB is an employee of Roche Products Ltd. LVH is an employee of AstraZeneca. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.